
No.: PCT/EP00/05852 International Applicat Attorney Docket No.: BM45395



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Thonnard Docket No.: BM45395 Serial No.: Unknown

Filed: Herewith

Group Art Unit No.: Unknown

Examiner: Unknown

For: BASB111 Polypeptide and Polynucleotide From Moraxella Catharrhalis

PRELIMINARY AMENDMENT

Sir:

Applicant respectfully requests that this Preliminary Amendment be entered in this case before the calculation of fees and before examination of the subject application.

In the Claims:

Please delete the claims of the application as filed in the PCT and substitute therefor:

An isolated polypeptide comprising a member selected from the group consisting of

- an amino acid sequence matching SEQ ID NO:2 and (a)
- an immunogenic polypeptide comprising a fragment sequence of at least 15 (b) amino acids that matches an aligned contiguous segment of SEQ ID NO:2, wherein the isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell immune response to a polypeptide having the sequence of SEQ ID NO:2.

29 An isolated polynucleotide encoding a polypeptide of Claim 27 or the full complement 28. to the isolated polynucleotide.

The isolated polypeptide of claim 27, wherein the polypeptide is according to (a).

An isolated polynucleotide encoding a polypeptide of Claim 29 or the full complement to the isolated polynucleotide.

32 A process for expressing the polynucleotide of Claim 30 comprising transforming a *31*. host cell with an expression vector comprising the polynucleotide and culturing the host cell under conditions sufficient for expression of the polynucleotide.